Generation shift of ALK targeted drugs... rise of Alecensa
By | translator Alice Kang
22.03.07 16:37:55
가나다라
0
1st generation Xalkori's sales fall… market share falls from 86%→24% in 4 years
'Alecensa' occupies over half of the market…latecomer ‘Alunbrig’ is on a fierce chase
First 3rd generation ‘Lorviqua’ introduced to the market… rises as a new alternative in the second-line
The targeted cancer therapy market for patients with ALK mutations has been restructured around second-generation drugs. The share of the first-generation drug Xalkori, which used to occupy 2/3 of the market fell to 20%, and the representative second-generation drug ‘Alecensa' took over the market. However, Alunbrig, a latecomer into the second-generation treatment market, has been rapidly chasing the market leader Alecensa that has currently occupied over half of the market.
According to the pharmaceutical research institution IQVIA on the 8th, the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor (TKI) market recorded ₩54.4 billion last year, which was an 11.9% and ₩48.6 billion inc
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)